SOM 0777
Alternative Names: JLB 137; SOM 0777Latest Information Update: 03 Mar 2023
Price :
$50 *
At a glance
- Originator SOM Biotech
- Developer SOM Biotech; U-Cell Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 03 Mar 2023 Phase-I clinical trials in Glioblastoma in Spain (PO) (SOM Biotech pipeline, March 2023)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Glioblastoma in Spain (PO)
- 27 Oct 2020 Preclinical development is ongoing in Spain (SOM Biotech website, October 2020)